Validated purity, strict cGMP compliance, and dedicated supply chain integration for biopharmaceutical enterprises in Georgia and worldwide.
An in-depth analysis of targeted anticancer therapies, chemical synthesis containment, and regional pharmaceutical procurement resilience.
The global pharmaceutical sector is undergoing a profound structural shift toward targeted small-molecule therapeutics, tyrosine kinase inhibitors (TKIs), and specialized immunosuppressive regimens. Within this evolving framework, the region of Georgia—serving both as a major bio-innovation cluster in the Southeastern United States and a critical strategic trade corridor in Eurasia—has materialized as a vital focal point for high-potency active pharmaceutical ingredient (HPAPI) sourcing, contract development, and advanced chemical manufacturing (CDMO).
As academic institutions, medical centers of excellence, and commercial bio-incubators expand across Georgia, the demand for enterprise-grade Anticancer Drugs Manufacturers and Factory Partners has risen exponentially. Formulators, generic pharmaceutical producers, and clinical R&D units require uncompromised access to high-purity (≥99%) APIs, rigorous analytical characterization, and reliable cold-chain fulfillment to safeguard pipeline integrity and maintain regulatory compliance with the US FDA, EMA, and international health authorities.
The pharmaceutical industry faced severe disruptions over the past decade due to localized raw material bottlenecks, single-source dependency, and escalating compliance demands regarding heavy metals, elemental impurities (ICH Q3D), and residual solvents (ICH Q3C). Oncology therapeutics represent a zero-tolerance category: supply chain stockouts directly compromise patient outcomes, while sub-standard chemical purity can introduce toxic side-effects or lead to immediate batch rejections during dosage form compounding.
Our operational model bridges advanced research laboratories with industrial-scale manufacturing infrastructure. By maintaining robust stock levels of key oncology intermediates—such as Tacrolimus, Cabozantinib, Ceritinib, Ponatinib, Ibrutinib, and Dasatinib—we enable healthcare companies, university researchers, and pharmaceutical factories in Georgia to secure critical raw materials with complete batch traceability, Certificates of Analysis (CoA), HPLC purity chromatograms, and NMR spectrum validations.
Every batch of oncology raw material destined for Georgian facilities undergoes rigorous multi-stage analytical testing, including chiral purity verification, polymorph screening via PXRD, mass spectrometry (MS), and gas chromatography for residual solvents. This ensures seamless scale-up from pilot lab synthesis to multi-kilogram commercial dosage manufacturing.
Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients, pharmaceutical intermediates, nutritional products and food additives, cooperative R & D, custom manufacturing, sales and service as well as import of these kinds of materials.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provide factory quality management system certification consulting services.
Internationally, we have long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets, and provides products in the whole process of market and sales services. At the same time, we also provide product registration, consulting and sales channel expansion services for overseas companies in the Chinese market, as well as specialized distribution networks servicing partners throughout Georgia and North America.
Our anticancer active pharmaceutical ingredients, high-potency targeted molecules, and specialized chemical intermediates are engineered to support full-spectrum drug development and industrial production across global and Georgian healthcare facilities.
State-of-the-art reactor trains, containment systems, and batch processing controls built to fulfill rigorous international standard operating procedures.
We are able to assemble and produce larger quantities of intermediates and provide some advanced, convenient manufacturing capabilities, including batch processing and customization.
For the company's main product intermediates: We can maximize our advantages, meet the requirements of most customers and complete the task within the specified time limit.
| Compound Name | CAS Number | Therapeutic Target / Class | Standard Assay Purity | Primary Application |
|---|---|---|---|---|
| Tacrolimus | 104987-11-3 | Macrolide Immunosuppressive / Calcineurin Inhibitor | ≥ 99.0% | Post-transplant immunosuppression & oncology adjuncts |
| Cabozantinib | 849217-68-1 / 849217-48-7 | Multi-kinase Inhibitor (VEGFR2, MET, RET) | ≥ 99.5% | Renal cell carcinoma, medullary thyroid cancer treatment |
| Ceritinib | 1032900-25-6 | ALK Inhibitor | ≥ 99.0% | ALK-positive metastatic non-small cell lung cancer (NSCLC) |
| Ponatinib | 943319-70-8 | Pan-BCR-ABL Tyrosine Kinase Inhibitor | ≥ 99.5% | CML and Ph+ ALL target therapy synthesis |
| Ibrutinib | 936563-96-1 | Bruton's Tyrosine Kinase (BTK) Inhibitor | ≥ 99.5% | Mantle cell lymphoma, chronic lymphocytic leukemia |
| Dasatinib Monohydrate | 863127-77-9 | Dual Src/Abl Tyrosine Kinase Inhibitor | ≥ 99.0% | Acute lymphoblastic leukemia & CML formulations |
| Afatinib | 850140-72-6 | Irreversible ErbB Family Blocker | ≥ 99.0% | EGFR-mutated non-small cell lung carcinoma therapeutics |
| Paclitaxel | 33069-62-4 | Microtubule-Stabilizing Cytotoxic Agent | ≥ 99.0% | Ovarian, breast, and non-small cell lung cancers |
Comprehensive regulatory support, tech transfer assistance, and streamlined delivery across Georgia and international destinations.
Full access to Drug Master Files (DMFs), analytical validation packages, and regulatory audit support. Our team provides factory quality management system certification consulting services tailored to regional compliance bodies.
Temperature-sensitive active pharmaceutical ingredients require specialized handling. We offer validated insulated packaging, real-time data loggers, and express customs clearance into Georgia biopharmaceutical hubs.
From gram-scale laboratory research quantities to multi-ton industrial batches, our collaborative R&D team executes high-potency chemical synthesis under custom non-disclosure agreements (NDAs).
Explore our comprehensive product selection of certified active pharmaceutical ingredients and high-purity chemical intermediates.
Expert insights regarding procurement, technical specifications, regulatory filings, and delivery to Georgia.
All active pharmaceutical ingredients and oncology intermediates are manufactured under cGMP-compliant systems (ICH Q7). Each batch is supplied with comprehensive CoA, HPLC, H-NMR, MS, and loss on drying (LOD) documentation to meet US FDA and European Pharmacopoeia standards.
We provide full-process supply chain support for Georgian pharmaceutical facilities, including customs documentation, temperature-controlled freight, batch-to-batch consistency guarantees, and technical consulting for quality management system certification.
Yes. Our collaborative R&D center in Hangzhou specializes in custom synthesis of complex heterocyclic intermediates and high-potency molecules (HPAPIs) from scale-up pilot lots to industrial commercial scale.
We accommodate both R&D trial quantities (e.g., 100g – 1kg) for academic/clinical evaluation as well as multi-hundred kilogram production runs for commercial manufacturing partners in Georgia and internationally.
Secure high-purity oncology APIs, request technical dossiers, or request custom CDMO quotes today.
Send Inquiry Now
SJ medical
